Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events
The Oncologist · 08.05.2023 · 28 (5) · 440-448
DOI: 10.1093/oncolo/oyac252 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 03.01.2023. Verfasst von Kristen Mathias und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Arthritis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Side effects of immune checkpoint inhibitors (ICIs), called immune-related adverse events (irAEs), closely resemble primary autoimmune or rheumatic diseases. We aimed to understand the clinical utility of rheumatic autoantibodies (rhAbs) for diagnosing irAEs. Patients and Methods Patients without pre-existing autoimmune disease (pAID) who had cancer treated with ICI(s) treatment from 1/1/2011 to 12/21/2020 and a rhAb checked were retrospectively identified. Logistic regression assessed associations between autoantibodies and irAEs, cancer outcome, and survival. Specificity, sensitivity, and positive/negative predictive values (PPV, NPV) were estimated for key rhAbs and ICI-arthritis. Kaplan-Meier analyzed objective response rate (ORR) and overall survival (OS).
Results
A total of 2662 patients were treated with≥1 ICIs. One hundred and thirty-five without pAID had ≥ 1 rhAb tested. Of which 70/135(52%) were female; median age at cancer diagnosis was 62 years with most common cancers: melanoma (23%) or non–small cell lung cancer (21%), 96/135 (75%) were anti-PD1/PDL1 treated. Eighty had a rhAb ordered before ICI, 96 after ICI, and 12 before and after. Eighty-two (61%) experienced an irAE, 33 (24%) with rheumatic-irAE. Pre-ICI RF showed significant association with rheumatic-irAEs (OR = 25, 95% CI, 1.52-410.86, P = .024). Pre– and post–ICI RF yielded high specificity for ICI-arthritis (93% and 78%), as did pre– and post–ICI CCP (100% and 91%). Pre–ICI RF carried 93% NPV and pre–ICI CCP had 89% PPV for ICI-arthritis. No variables were significantly correlated with ORR. Any-type irAE, rheumatic-irAE and ICI-arthritis were all associated with better OS (P = .000, P = .028, P = .019).
Conclusions
Pre–ICI RF was associated with higher odds of rheumatic-irAEs. IrAEs had better OS; therefore, clinical contextualization for rhAbs is critical to prevent unnecessary withholding of lifesaving ICI for fear of irAEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA.
- Department of Medicine, Section of Hematology Oncology, Chicago, IL, USA.
- Department of Medicine, Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA.
- Committee on Clinical Pharmacology and Pharmacogenomics, Chicago, IL, USA.
- Department of Medicine, Section of Rheumatology, University of Chicago Medical Center, Chicago, IL, USA.
ORCID-Profile: Sherin Rouhani, Anne R Bass, Thomas F Gajewski, Pankti Reid
Zitieren
APA
Mathias, K., Rouhani, S., Olson, D., Bass, A. R., Gajewski, T. F., & Reid, P. (2023). Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events. The Oncologist, 28(5), 440-448. https://doi.org/10.1093/oncolo/oyac252
Vancouver
Mathias K, Rouhani S, Olson D, Bass AR, Gajewski TF, Reid P. Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events. The Oncologist. 2023;28(5):440-448. doi:10.1093/oncolo/oyac252
BibTeX
@article{Mathias2023,
author = {Mathias, Kristen and Rouhani, Sherin and Olson, Daniel and Bass, Anne R and Gajewski, Thomas F and Reid, Pankti},
title = {Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events},
journal = {The Oncologist},
year = {2023},
volume = {28},
number = {5},
pages = {440--448},
doi = {10.1093/oncolo/oyac252}
}
EUVIMED